Pacific Biomarkers' Dr. Amar A. Sethi Honored by Pharmaceutical Executive Magazine as One of 30 Emerging Pharma Leaders of 2011
News Jun 29, 2011
Pacific Biomarkers, Inc., has announced that Amar A. Sethi, MD, PhD, the Company's Vice President of Research and Development, has been named one of 30 emerging pharma leaders in the June 2011 issue of Pharmaceutical Executive.
An article titled "Emerging Pharma Leaders 2011: Managing in the Era of Lean" includes profiles of 30 individuals. The profile for Dr. Sethi begins, "An academic background in clinical chemistry combined with a solid understanding of a key therapeutic segment - lipid control medications - set the foundation for Pacific Biomarkers vice president for research and development Dr. Amar Sethi's career as a pathfinder in drug development."
"We are very pleased and proud that Amar has been recognized with this distinguished honor. PBI is extremely fortunate to have a physician-scientist of Dr. Sethi's stature as a valuable member of our team," said Ron Helm, PBI's Chairman and Chief Executive Officer.
Helm continued, "PBI is committed to scientific and commercial excellence as our fundamental mission to develop novel biomarkers, and Dr. Sethi's leadership in spearheading our efforts exemplifies this commitment."
Mr. Helm concluded by saying: "Dr. Sethi's leadership and experience will continue to play a major role in the company's initiatives for the development of custom biomarker services and custom assay development in the rapidly growing clinical biomarker space."
Dr. Sethi, along with the 29 others, will be honored at a dinner in October.
Genome-wide association studies (GWAS) look at large populations to find genes that contribute to common, multi-gene traits like height or obesity. These comprehensive studies frequently turn up large numbers of tiny genetic variations that occur more often in people who are tall, obese, etc. So which genes should scientists investigate further?READ MORE